CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $130.37M, above the global median of $16.24M
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.89%Above 5Y avg (1.90%)
Annual Rate
CNY 0.64Paid annual
Payout Ratio
51.2%Sustainable
Payback Period
20.5 yr
Last Ex-Dividend
May 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.10BCNY907.37M · vs all stocks (USD)
Trailing P/E
16.13xvs Biotechnology peers
Revenue (TTM)
932.09MCNY138.61M · vs all stocks (USD)
Profit Margin
41.81%vs Biotechnology peers
Beta
0.3430xvs all stocks
52-Week Change
-25.75%vs all stocks
Market Capitalization
6.10BCNY907.37M · vs all stocks (USD)
Enterprise Value
3.55BCNY528.35M · vs all stocks (USD)
Trailing P/E
16.13xvs Biotechnology peers
Forward P/E
13.55xvs Biotechnology peers
Price to Sales (TTM)
6.78xvs Biotechnology peers
Price to Book (MRQ)
1.46xvs Biotechnology peers
Enterprise to Revenue
3.81xvs Biotechnology peers
Enterprise to EBITDA
7.79xvs Biotechnology peers
Gross Margin
64.00%vs Biotechnology peers
Profit Margin
41.81%vs Biotechnology peers
Operating Margin
35.72%vs Biotechnology peers
Return on Assets (TTM)
4.54%vs Biotechnology peers
Return on Equity (TTM)
9.26%vs Biotechnology peers
Revenue (TTM)
932.09MCNY138.61M · vs all stocks (USD)
Revenue per Share (TTM)
2.01CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-7.20%vs Biotechnology peers
Gross Profit (TTM)
603.13MCNY89.69M · vs all stocks (USD)
EBITDA (TTM)
450.12MCNY66.94M · vs all stocks (USD)
Net Income (TTM)
389.72MCNY57.96M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-26.80%vs Biotechnology peers
Operating Cash Flow (TTM)
378.98MCNY56.36M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
876.66MCNY130.37M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6400CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
4.89%vs all stocks
5-Year Average Dividend Yield
1.90%vs all stocks
Payout Ratio
51.19%vs Biotechnology peers
Minority Interest (Equity)
397.45KCNYFY2025 · Dec 31, 2025Revenue
949.74MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
313.67MCNYFY2025 · Dec 31, 2025Gross Profit
636.07MCNYFY2025 · Dec 31, 2025Operating Income
388.23MCNY57.73M · vs all stocks (USD)
Pre-tax Income
481.54MCNYFY2025 · Dec 31, 2025Income Tax Expense
64.60MCNYFY2025 · Dec 31, 2025Net Income
416.94MCNYFY2025 · Dec 31, 2025EBIT
479.77MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
562.69MCNYFY2025 · Dec 31, 2025Research & Development
96.41MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
64.05MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.16MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
56.42MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
-1.77MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.9000CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.9000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
465.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
465.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
416.94MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
397.05MCNYFY2025 · Dec 31, 2025Free Cash Flow
280.93MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
176.80MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
416.94MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-44.02MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
54.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-30.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-116.12MCNYFY2025 · Dec 31, 2025Net Acquisitions
-4.50MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.94BCNYFY2025 · Dec 31, 2025Sale of Investments
1.41BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-648.89MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-199.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
15.21MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-184.27MCNYFY2025 · Dec 31, 2025Shares Outstanding
466.13MSharesUpdated Aug 21, 2026Float Shares
111.70MSharesUpdated Aug 21, 2026% Held by Insiders
74.70%vs all stocks
% Held by Institutions
1.83%vs all stocks
Total Cash (MRQ)
2.60BCNY386.11M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.57CNYUpdated Aug 21, 2026Total Debt (MRQ)
6.34MCNY942.29K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0015xvs Biotechnology peers
Current Ratio (MRQ)
7.42xvs Biotechnology peers
Book Value per Share (MRQ)
9.25CNYUpdated Aug 21, 2026Total Assets
4.79BCNY712.20M · vs all stocks (USD)
Total Current Assets
2.93BCNYFY2025 · Dec 31, 2025Total Liabilities
550.03MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.86BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
92.53MCNYFY2025 · Dec 31, 2025Total Current Liabilities
457.50MCNYFY2025 · Dec 31, 2025Cash
175.81MCNYFY2025 · Dec 31, 2025Cash Equivalents
990.44KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
176.80MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.54BCNYFY2025 · Dec 31, 2025Accounts Receivable
285.15MCNYFY2025 · Dec 31, 2025Inventory
144.27MCNYFY2025 · Dec 31, 2025Accounts Payable
111.32MCNYFY2025 · Dec 31, 2025Short-term Debt
1.61MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.12MCNYFY2025 · Dec 31, 2025Long-term Debt
5.07MCNYFY2025 · Dec 31, 2025Common Stock (Book)
466.13MCNYFY2025 · Dec 31, 2025Retained Earnings
2.37BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.24BCNY630.41M · vs all stocks (USD)
Treasury Stock
17.69MCNYFY2025 · Dec 31, 202552-Week Low
11.65CNYUpdated Aug 21, 202652-Week High
20.39CNYUpdated Aug 21, 202652-Week Change
-25.75%vs all stocks
Beta
0.3430xvs all stocks
50-Day MA
12.70CNYUpdated Aug 21, 2026200-Day MA
14.72CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.97MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.67MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.8400CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
Altman Z-Score 8.5: safe zoneNotable
Altman Z-Score: 8.50
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $130.37M, above the global median of $16.24MNotable
Levered free cash flow (USD): 130,367,485.208Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
LB Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Rightmove plc
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Dolby Laboratories Inc.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Imeik Technology Development Co., Ltd.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity